IFN gamma - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.10 [0.02, 57.31]< 10%1 study (1/-)48.1 %NAnot evaluable crucial-
clinical deterioration 2.29 [0.20, 26.58]< 10%1 study (1/-)25.6 %NAnot evaluable important-
viral clearance 3.26 [1.53, 6.95]> 10%1 study (1/-)99.9 %NAnot evaluable important-
viral clearance (time to event analysis only) 3.26 [1.53, 6.95]> 10%1 study (1/-)99.9 %NAnot evaluable important-
viral clearance by day 14 5.90 [0.28, 122.94]> 10%1 study (1/-)87.1 %NAnot evaluable important-
viral clearance by day 7 3.09 [1.04, 9.17]> 10%1 study (1/-)97.9 %NAnot evaluable important-

safety endpoints 00

adverse events 1.33 [0.45, 3.92]< 10%1 study (1/-)30.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.